Mesenchymal Stem Cell-based Therapy and Female Infertility: Limitations
and Advances

Ghazal      Ghajari; Arefe      Heydari; Masoud      Ghorbani
doi:10.2174/1574888X17666220511142930
Abstract

Infertility in women can be caused by various female reproductive diseases such as premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis and Asherman syndrome that affect couples' quality of life and lead to mental, emotional, and physical problems. In recent years, clinical researchers have sought infertility treatments using new methods that are more effective and noninvasive than the old methods.
Today, stem cell-based therapy has been introduced as a promising method and an alternative to the old strategy of infertility treatment. Understanding the main features and functional perspective of mesenchymal stem cells (MSCs) in the future of infertility by physicians is crucial.
Mesenchymal stem cells (MSCs) are multipotent stem cells with a high proliferation range, abundant source and multidirectional differentiation potential. They have a high potential for the treatment of injured tissues in regenerative medicine through cell homing, secretion of active factors, and participation in immune regulation. At present, due to fewer ethical restrictions on the use of mesenchymal stem cells compared to embryonic stem cells, more attention has been paid to these cells as a new treatment for gynecological disorders. In this paper, we first review the various type of female reproductive disorders along with their common treatment methods, then we evaluate the recent advances in the application of MSCs in the diseases related to infertility and improve the reproductive health of women worldwide.
Keywords: Pluripotent stem cell, female reproduction, assisted reproductive technologies, biotechnologies of reproduction, cell-based therapy, mesenchymal stem cells.
« Previous Next »
Graphical Abstract

[1]
Ghaebi M, Abdolmohammadi-Vahid S, Ahmadi M, et al. T cell subsets in peripheral blood of women with recurrent implantation failure. J Reprod Immunol  2019; 131: 21-9.
 [http://dx.doi.org/10.1016/j.jri.2018.11.002] [PMID:  30471511]

[2]
Ghajari G, Nabiuni M, Amini E. The association between testicular toxicity induced by Li2Co3 and protective effect of Ganoderma lucidum: Alteration of Bax & c-Kit genes expression. Tissue Cell  2021; 72: 101552.
 [http://dx.doi.org/10.1016/j.tice.2021.101552] [PMID:  33992978]

[3]
Sun H, Gong T-T, Jiang Y-T, Zhang S, Zhao Y-H, Wu Q-J. Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study, 2017. Aging (Albany NY)  2019; 11(23): 10952-91.
 [http://dx.doi.org/10.18632/aging.102497] [PMID:  31790362]

[4]
Ramírez González, Juan Andrés, et al. Overview of the female reproductive system Exercise and Human Reproduction.   2016; pp. 19-46.

[5]
Rendi MH, Muehlenbachs A, Garcia RL, Boyd KL. Female reproductive system Comparative anatomy and histology.  Elsevier 2012; pp. 253-84.
 [http://dx.doi.org/10.1016/B978-0-12-381361-9.00017-2]

[6]
Richards JS, Pangas SA. The ovary: basic biology and clinical implications. J Clin Invest  2010; 120(4): 963-72.
 [http://dx.doi.org/10.1172/JCI41350] [PMID:  20364094]

[7]
Jones RE, Lopez KH. Human reproductive biology. Academic Press 2013.

[8]
Sheikhansari G, Aghebati-Maleki L, Nouri M, Jadidi-Niaragh F, Yousefi M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomed Pharmacother  2018; 102: 254-62.
 [http://dx.doi.org/10.1016/j.biopha.2018.03.056] [PMID:  29567538]

[9]
Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol  2010; 45(5): 257-79.
 [http://dx.doi.org/10.1677/JME-10-0070] [PMID:  20668067]

[10]
Zhao Y, Ma J, Yi P, et al. Human umbilical cord mesenchymal stem cells restore the ovarian metabolome and rescue premature ovarian insufficiency in mice. Stem Cell Res Ther  2020; 11(1): 466.
 [http://dx.doi.org/10.1186/s13287-020-01972-5] [PMID:  33148334]

[11]
Crain DA, Janssen SJ, Edwards TM, et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil Steril  2008; 90(4): 911-40.
 [http://dx.doi.org/10.1016/j.fertnstert.2008.08.067] [PMID:  18929049]

[12]
Salazar CA, Isaacson K, Morris S. A comprehensive review of Asherman’s syndrome: causes, symptoms and treatment options. Curr Opin Obstet Gynecol  2017; 29(4): 249-56.
 [http://dx.doi.org/10.1097/GCO.0000000000000378] [PMID:  28582327]

[13]
Bai X. Stem Cell-Based Disease Modeling and Cell Therapy.  Multidisciplinary Digital Publishing Institute 2020; p. 2193.

[14]
Gargett CE, Masuda H. Adult stem cells in the endometrium. Mol Hum Reprod  2010; 16(11): 818-34.
 [http://dx.doi.org/10.1093/molehr/gaq061] [PMID:  20627991]

[15]
Schwab KE, Chan RWS, Gargett CE. Putative stem cell activity of human endometrial epithelial and stromal cells during the menstrual cycle. Fertil Steril  2005; 84 (Suppl. 2): 1124-30.
 [http://dx.doi.org/10.1016/j.fertnstert.2005.02.056] [PMID:  16210003]

[16]
Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol  2005; 21: 605-31.
 [http://dx.doi.org/10.1146/annurev.cellbio.21.012704.131525] [PMID:  16212509]

[17]
Park H-S, Ashour D, Elsharoud A, et al. Towards cell free therapy
of premature ovarian insufficiency: human bone marrow mesenchymal
stem cells secretome enhances angiogenesis in human ovarian
microvascular endothelial cells HSOA J Stem Cells Res Dev
Ther  2019; 5(2)

[18]
Ballini A, Boccaccio A, Saini R, Van Pham P, Tatullo M. Dental-derived stem cells and their secretome and interactions with bioscaffolds/biomaterials in regenerative medicine: From the in vitro research to translational applications. Hindawi 2017.

[19]
Rungsiwiwut R, Virutamasen P, Pruksananonda K. Mesenchymal stem cells for restoring endometrial function: An infertility perspective. Reprod Med Biol  2020; 20(1): 13-9.
 [http://dx.doi.org/10.1002/rmb2.12339] [PMID:  33488279]

[20]
Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update  2015; 21(6): 748-61.
 [http://dx.doi.org/10.1093/humupd/dmv038] [PMID:  26253932]

[21]
Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med  2020; 382(13): 1244-56.
 [http://dx.doi.org/10.1056/NEJMra1810764] [PMID:  32212520]

[22]
Navarro R, Poder L, Sun D, Jha P. Endometriosis in pregnancy. Abdom Radiol (NY)  2020; 45(6): 1741-53.
 [http://dx.doi.org/10.1007/s00261-020-02486-7] [PMID:  32206832]

[23]
Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vanderkerchove P. Ovulation suppression for endometriosis for women with subfertility.  Cochrane Database Sys Rev 2007; p. 3.
 [http://dx.doi.org/10.1002/14651858.CD000155.pub2]

[24]
Ahmad G, Baker J, Finnerty J, Phillips K, Watson A. Laparoscopic entry techniques. Cochrane Database of systematic review  2019; 1.
 [http://dx.doi.org/10.1002/14651858.CD006583.pub5]

[25]
Lee D, Kim SK, Lee JR, Jee BC. Management of endometriosis-related infertility: Considerations and treatment options. Clin Exp Reprod Med  2020; 47(1): 1-11.
 [http://dx.doi.org/10.5653/cerm.2019.02971] [PMID:  32088944]

[26]
Benor A, Gay S, DeCherney A. An update on stem cell therapy for Asherman syndrome. J Assist Reprod Genet  2020; 37(7): 1511-29.
 [http://dx.doi.org/10.1007/s10815-020-01801-x] [PMID:  32445154]

[27]
Dreisler E, Kjer JJ. Asherman’s syndrome: current perspectives on diagnosis and management. Int J Womens Health  2019; 11: 191-8.
 [http://dx.doi.org/10.2147/IJWH.S165474] [PMID:  30936754]

[28]
Di Guardo F, Della Corte L, Vilos GA, et al. Evaluation and treatment of infertile women with Asherman syndrome: an updated review focusing on the role of hysteroscopy. Reprod Biomed Online  2020; 41(1): 55-61.
 [http://dx.doi.org/10.1016/j.rbmo.2020.03.021] [PMID:  32444259]

[29]
Esfandyari S, Chugh RM, Park HS, Hobeika E, Ulin M, Al-Hendy A. Mesenchymal stem cells as a bio organ for treatment of female infertility. Cells  2020; 9(10): 2253.
 [http://dx.doi.org/10.3390/cells9102253] [PMID:  33050021]

[30]
Tan J, Li P, Wang Q, et al. Autologous menstrual blood-derived stromal cells transplantation for severe Asherman’s syndrome. Hum Reprod  2016; 31(12): 2723-9.
 [http://dx.doi.org/10.1093/humrep/dew235] [PMID:  27664218]

[31]
Zhao Y, Luo Q, Zhang X, et al. Clinical efficacy and safety of stem cell-based therapy in treating asherman syndrome: A system review and meta-analysis Stem Cells Int   2020; 2020
 [http://dx.doi.org/10.1155/2020/8820538]

[32]
Bahrehbar K, Rezazadeh Valojerdi M, Esfandiari F, Fathi R, Hassani S-N, Baharvand H. Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure. World J Stem Cells  2020; 12(8): 857-78.
 [http://dx.doi.org/10.4252/wjsc.v12.i8.857] [PMID:  32952863]

[33]
Ghahremani-Nasab M, Ghanbari E, Jahanbani Y, Mehdizadeh A, Yousefi M. Premature ovarian failure and tissue engineering. J Cell Physiol  2020; 235(5): 4217-26.
 [http://dx.doi.org/10.1002/jcp.29376] [PMID:  31663142]

[34]
Jankowska K. Premature ovarian failure. Menopause Rev  2017; 16(2): 51.
 [http://dx.doi.org/10.5114/pm.2017.68592]

[35]
He Y, Chen D, Yang L, Hou Q, Ma H, Xu X. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res Ther  2018; 9(1): 263.
 [http://dx.doi.org/10.1186/s13287-018-1008-9] [PMID:  30286808]

[36]
Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev  2016; 37(5): 467-520.
 [http://dx.doi.org/10.1210/er.2015-1104] [PMID:  27459230]

[37]
Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol  2018; 34(4): 272-7.
 [http://dx.doi.org/10.1080/09513590.2017.1395841] [PMID:  29084464]

[38]
Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol  2018; 182: 27-36.
 [http://dx.doi.org/10.1016/j.jsbmb.2018.04.008] [PMID:  29678491]

[39]
Piparva KG, Buch JG. Deep vein thrombosis in a woman taking oral combined contraceptive pills. J Pharmacol Pharmacother  2011; 2(3): 185-6.
 [http://dx.doi.org/10.4103/0976-500X.83284] [PMID:  21897713]

[40]
Yang PK, Hsu CY, Chen MJ, et al. The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab  2018; 103(3): 890-9.
 [http://dx.doi.org/10.1210/jc.2017-01739] [PMID:  29325133]

[41]
Howie R, Kay V. Controlled ovarian stimulation for in-vitro fertilization. Br J Hosp Med (Lond)  2018; 79(4): 194-9.
 [http://dx.doi.org/10.12968/hmed.2018.79.4.194] [PMID:  29620984]

[42]
Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol  2020; 76(14): 1690-702.
 [http://dx.doi.org/10.1016/j.jacc.2020.08.014] [PMID:  33004135]

[43]
Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. J Pregnancy  2011; 2011: 214365.
 [http://dx.doi.org/10.1155/2011/214365] [PMID:  21547086]

[44]
Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol  2012; 36(1): 56-9.
 [http://dx.doi.org/10.1053/j.semperi.2011.09.011] [PMID:  22280867]

[45]
Armaly Z, Jadaon JE, Jabbour A, Abassi ZA. Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. Front Physiol  2018; 9: 973.
 [http://dx.doi.org/10.3389/fphys.2018.00973] [PMID:  30090069]

[46]
Jim B, Karumanchi SA. Preeclampsia: pathogenesis, prevention, and long-term complications. Semin Nephrol  2017; 37(4): 386-97.
 [http://dx.doi.org/10.1016/j.semnephrol.2017.05.011] [PMID:  28711078]

[47]
Wang LL, Yu Y, Guan HB, Qiao C. Effect of human umbilical cord mesenchymal stem cell transplantation in a rat model of preeclampsia. Reprod Sci  2016; 23(8): 1058-70.
 [http://dx.doi.org/10.1177/1933719116630417] [PMID:  26887428]

[48]
Stentz NC, Koelper N, Barnhart KT, Sammel MD, Senapati S. Infertility and mortality   Am J Obstet Gynecol  2020; 222(3): 251-e1-.e10.
 [http://dx.doi.org/10.1016/j.ajog.2019.09.007]

[49]
Wang Z, Wei Q, Wang H, et al. Mesenchymal stem cell therapy using human umbilical cord in a rat model of autoimmune-induced premature ovarian failure. Stem Cells Int  2020; 2020: 3249495.
 [http://dx.doi.org/10.1155/2020/3249495] [PMID:  32714395]

[50]
Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res  2013; 113(6): 810-34.
 [http://dx.doi.org/10.1161/CIRCRESAHA.113.300219] [PMID:  23989721]

[51]
Tibbetts MD, Samuel MA, Chang TS, Ho AC. Stem cell therapy for retinal disease. Curr Opin Ophthalmol  2012; 23(3): 226-34.
 [http://dx.doi.org/10.1097/ICU.0b013e328352407d] [PMID:  22450217]

[52]
Martínez Morales PL, Revilla. A, Ocaña I, et al. Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev Rep  2013; 9(5): 685-99.
 [http://dx.doi.org/10.1007/s12015-013-9443-6] [PMID:  23681704]

[53]
Volarevic V, Bojic S, Nurkovic J, et al. Stem cells as new agents for the treatment of infertility: current and future perspectives and challenges. BioMed Res Int  2014; 2014: 507234.
 [http://dx.doi.org/10.1155/2014/507234] [PMID:  24826378]

[54]
Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science  1997; 276(5309): 71-4.
 [http://dx.doi.org/10.1126/science.276.5309.71] [PMID:  9082988]

[55]
Chang Z, Zhu H, Zhou X, et al. Mesenchymal Stem Cells in Preclinical Infertility Cytotherapy: A Retrospective Review. Stem Cells Int  2021; 2021: 8882368.
 [http://dx.doi.org/10.1155/2021/8882368] [PMID:  34054970]

[56]
Neri S. Genetic stability of mesenchymal stromal cells for regenerative medicine applications: A fundamental biosafety aspect. Int J Mol Sci  2019; 20(10): E2406.
 [http://dx.doi.org/10.3390/ijms20102406] [PMID:  31096604]

[57]
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy  2006; 8(4): 315-7.
 [http://dx.doi.org/10.1080/14653240600855905] [PMID:  16923606]

[58]
Khan RS, Newsome PN. A comparison of phenotypic and functional properties of mesenchymal stromal cells and multipotent adult progenitor cells. Front Immunol  2019; 10: 1952.
 [http://dx.doi.org/10.3389/fimmu.2019.01952] [PMID:  31555259]

[59]
Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: Multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med  2017; 6(12): 2173-85.
 [http://dx.doi.org/10.1002/sctm.17-0129] [PMID:  29076267]

[60]
Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA  2002; 99(13): 8932-7.
 [http://dx.doi.org/10.1073/pnas.132252399] [PMID:  12084934]

[61]
Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol  2004; 94(1): 92-5.
 [http://dx.doi.org/10.1016/j.amjcard.2004.03.034] [PMID:  15219514]

[62]
Mun CH, Kang MI, Shin YD, Kim Y, Park YB. The expression of immunomodulation-related cytokines and genes of adipose- and bone marrow-derived human mesenchymal stromal cells from early to late passages. Tissue Eng Regen Med  2018; 15(6): 771-9.
 [http://dx.doi.org/10.1007/s13770-018-0147-5] [PMID:  30603595]

[63]
Mahla RS. Stem cells applications in regenerative medicine and disease therapeutics. Int J Cell Biol  2016; 2016: 6940283.
 [http://dx.doi.org/10.1155/2016/6940283] [PMID:  27516776]

[64]
Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol  2008; 36(10): 1370-6.
 [http://dx.doi.org/10.1016/j.exphem.2008.04.022] [PMID:  18619727]

[65]
Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood  2005; 105(7): 2821-7.
 [http://dx.doi.org/10.1182/blood-2004-09-3696] [PMID:  15591115]

[66]
Parsch D, Fellenberg J, Brümmendorf TH, Eschlbeck AM, Richter W. Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. J Mol Med (Berl)  2004; 82(1): 49-55.
 [http://dx.doi.org/10.1007/s00109-003-0506-z] [PMID:  14647922]

[67]
Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens UM. Lack of telomerase activity in human mesenchymal stem cells. Leukemia  2003; 17(6): 1146-9.
 [http://dx.doi.org/10.1038/sj.leu.2402962] [PMID:  12764382]

[68]
Zhao YX, Chen SR, Su PP, et al. Using mesenchymal stem cells to treat female infertility: An update on female reproductive diseases. Stem Cells Int  2019; 2019: 9071720.
 [http://dx.doi.org/10.1155/2019/9071720] [PMID:  31885630]

[69]
Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells  2019; 8(5): E467.
 [http://dx.doi.org/10.3390/cells8050467] [PMID:  31100966]

[70]
Cho J, Kim TH, Seok J, et al. Vascular remodeling by placenta-derived mesenchymal stem cells restores ovarian function in ovariectomized rat model via the VEGF pathway. Lab Invest  2021; 101(3): 304-17.
 [http://dx.doi.org/10.1038/s41374-020-00513-1] [PMID:  33303971]

[71]
Saribas GS, Ozogul C, Tiryaki M, Alpaslan Pinarli F, Hamdemir Kilic S. Effects of uterus derived mesenchymal stem cells and their exosomes on asherman’s syndrome. Acta Histochem  2020; 122(1): 151465.
 [http://dx.doi.org/10.1016/j.acthis.2019.151465] [PMID:  31776004]

[72]
Tsuji K, Kitamura S, Wada J. Secretomes from mesenchymal stem cells against acute kidney injury: Possible heterogeneity. Stem Cells Int  2018; 2018: 8693137.
 [http://dx.doi.org/10.1155/2018/8693137] [PMID:  30651737]

[73]
Tan JL, Lau SN, Leaw B, et al. Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair. Stem Cells Transl Med  2018; 7(2): 180-96.
 [http://dx.doi.org/10.1002/sctm.17-0185] [PMID:  29297621]

[74]
Zhang Q, Sun J, Huang Y, et al. Human amniotic epithelial cell-derived exosomes restore ovarian function by transferring micrornas against apoptosis. Mol Ther Nucleic Acids  2019; 16: 407-18.
 [http://dx.doi.org/10.1016/j.omtn.2019.03.008] [PMID:  31022607]

[75]
Yang M, Lin L, Sha C, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. Lab Invest  2020; 100(3): 342-52.
 [http://dx.doi.org/10.1038/s41374-019-0321-y] [PMID:  31537899]

[76]
Zhao S, Qi W, Zheng J, et al. Exosomes derived from adipose mesenchymal stem cells restore functional endometrium in a rat model of intrauterine adhesions. Reprod Sci  2020; 27(6): 1266-75.
 [http://dx.doi.org/10.1007/s43032-019-00112-6] [PMID:  31933162]

[77]
Jahanbani Y, Davaran S, Ghahremani-Nasab M, Aghebati-Maleki L, Yousefi M. Scaffold-based tissue engineering approaches in treating infertility. Life Sci  2020; 240: 117066.
 [http://dx.doi.org/10.1016/j.lfs.2019.117066] [PMID:  31738881]

[78]
Hutmacher DW. Scaffold design and fabrication technologies for engineering tissues--state of the art and future perspectives. J Biomater Sci Polym Ed  2001; 12(1): 107-24.
 [http://dx.doi.org/10.1163/156856201744489] [PMID:  11334185]

[79]
Abd-Allah SH, Shalaby SM, Pasha HF, et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. Cytotherapy  2013; 15(1): 64-75.
 [http://dx.doi.org/10.1016/j.jcyt.2012.08.001] [PMID:  23260087]

[80]
Badawy A, Sobh MA, Ahdy M, Abdelhafez MS. Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model. Int J Womens Health  2017; 9: 441-7.
 [http://dx.doi.org/10.2147/IJWH.S134074] [PMID:  28670143]

[81]
Fu X, He Y, Wang X, et al. Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to inhibit granulosa cell apoptosis. Stem Cell Res Ther  2017; 8(1): 187.
 [http://dx.doi.org/10.1186/s13287-017-0641-z] [PMID:  28807003]

[82]
Sun B, Ma Y, Wang F, Hu L, Sun Y. miR-644-5p carried by bone mesenchymal stem cell-derived exosomes targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. Stem Cell Res Ther  2019; 10(1): 360.
 [http://dx.doi.org/10.1186/s13287-019-1442-3] [PMID:  31783913]

[83]
I Cervelló, C Gil-Sanchis, X Santamaría, et al. Human CD133(+)bone marrow-derived stem cells promote endometrial proliferation	in a murine model of Asherman syndrome Fertil Steril  2015; 104(6): 1552-60.

[84]
Gao L, Huang Z, Lin H, Tian Y, Li P, Lin S. Bone marrow mesenchymal stem cells (BMSCs) restore functional endometrium in the rat model for severe asherman syndrome. Reprod Sci  2019; 26(3): 436-44.
 [http://dx.doi.org/10.1177/1933719118799201] [PMID:  30458678]

[85]
Sun M, Wang S, Li Y, et al. Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure. Stem Cell Res Ther  2013; 4(4): 80.
 [http://dx.doi.org/10.1186/scrt231] [PMID:  23838374]

[86]
Terraciano P, Garcez T, Ayres L, et al. Cell therapy for chemically induced ovarian failure in mice. Stem Cells Int  2014; 2014: 720753.
 [http://dx.doi.org/10.1155/2014/720753] [PMID:  25548574]

[87]
Su J, Ding L, Cheng J, et al. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency. Hum Reprod  2016; 31(5): 1075-86.
 [http://dx.doi.org/10.1093/humrep/dew041] [PMID:  26965432]

[88]
Kilic S, Yuksel B, Pinarli F, Albayrak A, Boztok B, Delibasi T. Effect of stem cell application on Asherman syndrome, an experimental rat model. J Assist Reprod Genet  2014; 31(8): 975-82.
 [http://dx.doi.org/10.1007/s10815-014-0268-2] [PMID:  24974357]

[89]
Liu T, Huang Y, Zhang J, et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. Stem Cells Dev  2014; 23(13): 1548-57.
 [http://dx.doi.org/10.1089/scd.2013.0371] [PMID:  24593672]

[90]
Zhong Z, Patel AN, Ichim TE, et al. Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med  2009; 7: 15.
 [http://dx.doi.org/10.1186/1479-5876-7-15] [PMID:  19232091]

[91]
Manshadi MD, Navid S, Hoshino Y, Daneshi E, Noory P, Abbasi M. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure. Microsc Res Tech  2019; 82(6): 635-42.
 [http://dx.doi.org/10.1002/jemt.23120] [PMID:  30582244]

[92]
Mohamed SA, Shalaby S, Brakta S, Elam L, Elsharoud A, Al-Hendy A. Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency. Biomedicines  2019; 7(1): E7.
 [http://dx.doi.org/10.3390/biomedicines7010007] [PMID:  30669278]

[93]
Elfayomy AK, Almasry SM, El-Tarhouny SA, Eldomiaty MA. Human umbilical cord blood-mesenchymal stem cells transplantation renovates the ovarian surface epithelium in a rat model of premature ovarian failure: Possible direct and indirect effects. Tissue Cell  2016; 48(4): 370-82.
 [http://dx.doi.org/10.1016/j.tice.2016.05.001] [PMID:  27233913]

[94]
Xie Q, Xiong X, Xiao N, et al. Mesenchymal stem cells alleviate dhea-induced polycystic ovary syndrome (PCOS) by inhibiting inflammation in mice. Stem Cells Int  2019; 2019: 9782373.
 [http://dx.doi.org/10.1155/2019/9782373] [PMID:  31611920]

[95]
Liu T, Huang Y, Guo L, Cheng W, Zou G. CD44+/CD105+ human amniotic fluid mesenchymal stem cells survive and proliferate in the ovary long-term in a mouse model of chemotherapy-induced premature ovarian failure. Int J Med Sci  2012; 9(7): 592-602.
 [http://dx.doi.org/10.7150/ijms.4841] [PMID:  23028242]

[96]
Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH, Wu SC. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci Rep  2016; 6: 23120.
 [http://dx.doi.org/10.1038/srep23120] [PMID:  26979400]

[97]
Chu DT, Phuong TNT, Tien NLB, et al. An update on the progress of isolation, culture, storage, and clinical application of human bone marrow mesenchymal stem/stromal cells. Int J Mol Sci  2020; 21(3): E708.
 [http://dx.doi.org/10.3390/ijms21030708] [PMID:  31973182]

[98]
Nasef A, Fouillard L, El-Taguri A, Lopez M. Human bone marrow-derived mesenchymal stem cells. Libyan J Med  2007; 2(4): 190-201.
 [http://dx.doi.org/10.3402/ljm.v2i4.4729] [PMID:  21503244]

[99]
Besikcioglu HE, GS Sarıbas, C Ozogul, et al. Determination of the effects of bone marrow derived mesenchymal stem cells and ovarian stromal stem cells on follicular maturation in cyclophosphamide induced ovarian failure in rats. Taiwan J Obstet Gynecol  2019; 58(1): 53-9.
 [http://dx.doi.org/10.1016/j.tjog.2018.11.010] [PMID:  30638481]

[100]
Kalhori Z, Azadbakht M, Soleimani Mehranjani M, Shariatzadeh MA. Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy  2018; 20(12): 1445-58.
 [http://dx.doi.org/10.1016/j.jcyt.2018.09.005] [PMID:  30523787]

[101]
Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril  2018; 110(3): 496-505.e1.
 [http://dx.doi.org/10.1016/j.fertnstert.2018.04.025] [PMID:  29960701]

[102]
Hassanshahi A, Hassanshahi M, Khabbazi S, et al. Adipose-derived stem cells for wound healing. J Cell Physiol  2019; 234(6): 7903-14.
 [http://dx.doi.org/10.1002/jcp.27922] [PMID:  30515810]

[103]
Damous LL, Nakamuta JS, Carvalho AE, et al. Does adipose tissue-derived stem cell therapy improve graft quality in freshly grafted ovaries? Reprod Biol Endocrinol  2015; 13: 108.
 [http://dx.doi.org/10.1186/s12958-015-0104-2] [PMID:  26394676]

[104]
Zhang C. The roles of different stem cells in premature ovarian failure. Curr Stem Cell Res Ther  2020; 15(6): 473-81.
 [http://dx.doi.org/10.2174/1574888X14666190314123006] [PMID:  30868961]

[105]
Lee SY, Shin JE, Kwon H, Choi DH, Kim JH. Effect of autologous adipose-derived stromal vascular fraction transplantation on endometrial regeneration in patients of asherman’s syndrome: A pilot study. Reprod Sci  2020; 27(2): 561-8.
 [http://dx.doi.org/10.1007/s43032-019-00055-y] [PMID:  32046396]

[106]
Meng X, Ichim TE, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med  2007; 5: 57.
 [http://dx.doi.org/10.1186/1479-5876-5-57] [PMID:  18005405]

[107]
Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther  2019; 10(1): 406.
 [http://dx.doi.org/10.1186/s13287-019-1503-7] [PMID:  31864423]

[108]
Lv H, Hu Y, Cui Z, Jia H. Human menstrual blood: a renewable and sustainable source of stem cells for regenerative medicine. Stem Cell Res Ther  2018; 9(1): 325.
 [http://dx.doi.org/10.1186/s13287-018-1067-y] [PMID:  30463587]

[109]
Abbaszadeh H, Ghorbani F, Derakhshani M, Movassaghpour A, Yousefi M. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm. J Cell Physiol  2020; 235(2): 706-17.
 [http://dx.doi.org/10.1002/jcp.29004] [PMID:  31254289]

[110]
Marino L, Castaldi MA, Rosamilio R, et al. Mesenchymal stem cells from the wharton’s jelly of the human umbilical cord: Biological properties and therapeutic potential. Int J Stem Cells  2019; 12(2): 218-26.
 [http://dx.doi.org/10.15283/ijsc18034] [PMID:  31022994]

[111]
Nekanti U, Mohanty L, Venugopal P, Balasubramanian S, Totey S, Ta M. Optimization and scale-up of Wharton’s jelly-derived mesenchymal stem cells for clinical applications. Stem Cell Res (Amst)  2010; 5(3): 244-54.
 [http://dx.doi.org/10.1016/j.scr.2010.08.005] [PMID:  20880767]

[112]
Fong CY, Richards M, Manasi N, Biswas A, Bongso A. Comparative growth behaviour and characterization of stem cells from human Wharton’s jelly. Reprod Biomed Online  2007; 15(6): 708-18.
 [http://dx.doi.org/10.1016/S1472-6483(10)60539-1] [PMID:  18062871]

[113]
Song D, Zhong Y, Qian C, et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. BioMed Res Int  2016; 2016: 2517514.
 [http://dx.doi.org/10.1155/2016/2517514] [PMID:  27047962]

[114]
Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial. Stem Cell Res Ther  2018; 9(1): 192.
 [http://dx.doi.org/10.1186/s13287-018-0904-3] [PMID:  29996892]

[115]
Ding L, Yan G, Wang B, et al. Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with long history of infertility. Sci China Life Sci  2018; 61(12): 1554-65.
 [http://dx.doi.org/10.1007/s11427-017-9272-2] [PMID:  29546669]

[116]
Berebichez-Fridman R, Montero-Olvera PR. Sources and clinical applications of mesenchymal stem cells: State-of-the-art review. Sultan Qaboos Univ Med J  2018; 18(3): e264-77.
 [http://dx.doi.org/10.18295/squmj.2018.18.03.002] [PMID:  30607265]

[117]
Magatti M, Vertua E, Cargnoni A, Silini A, Parolini O. The immunomodulatory properties of amniotic cells: The two sides of the coin. Cell Transplant  2018; 27(1): 31-44.
 [http://dx.doi.org/10.1177/0963689717742819] [PMID:  29562786]

[118]
Muttini A, Barboni B, Valbonetti L, Russo V, Maffulli N. Amniotic epithelial stem cells: Salient features and possible therapeutic role. Sports Med Arthrosc Rev  2018; 26(2): 70-4.
 [http://dx.doi.org/10.1097/JSA.0000000000000189] [PMID:  29722767]

[119]
Ding C, Li H, Wang Y, et al. Different therapeutic effects of cells derived from human amniotic membrane on premature ovarian aging depend on distinct cellular biological characteristics. Stem Cell Res Ther  2017; 8(1): 173.
 [http://dx.doi.org/10.1186/s13287-017-0613-3] [PMID:  28750654]

[120]
Loukogeorgakis SP, De Coppi P. Concise review: Amniotic fluid stem cells: The known, the unknown, and potential regenerative medicine applications. Stem Cells  2017; 35(7): 1663-73.
 [http://dx.doi.org/10.1002/stem.2553] [PMID:  28009066]

[121]
Xiao GY, Liu IH, Cheng CC, et al. Amniotic fluid stem cells prevent follicle atresia and rescue fertility of mice with premature ovarian failure induced by chemotherapy. PLoS One  2014; 9(9): e106538.
 [http://dx.doi.org/10.1371/journal.pone.0106538] [PMID:  25198549]

[122]
Azizi R, Aghebati-Maleki L, Nouri M, Marofi F, Negargar S, Yousefi M. Stem cell therapy in Asherman syndrome and thin endometrium: Stem cell- based therapy. Biomed Pharmacother  2018; 102: 333-43.
 [http://dx.doi.org/10.1016/j.biopha.2018.03.091] [PMID:  29571018]

[123]
Yang Y, Lei L, Wang S, et al. Transplantation of umbilical cord-derived mesenchymal stem cells on a collagen scaffold improves ovarian function in a premature ovarian failure model of mice. In Vitro Cell Dev Biol Anim  2019; 55(4): 302-11.
 [http://dx.doi.org/10.1007/s11626-019-00337-4] [PMID:  30820812]

[124]
Zhao G, Cao Y, Zhu X, et al. Transplantation of collagen scaffold with autologous bone marrow mononuclear cells promotes functional endometrium reconstruction via downregulating ∆Np63 expression in Asherman’s syndrome. Sci China Life Sci  2017; 60(4): 404-16.
 [http://dx.doi.org/10.1007/s11427-016-0328-y] [PMID:  27921235]

[125]
Saha S, Roy P, Corbitt C, Kakar SS. Application of stem cell therapy for infertility. Cells  2021; 10(7): 1613.
 [http://dx.doi.org/10.3390/cells10071613] [PMID:  34203240]

[126]
Ratajczak MZ, Ratajczak J, Kucia M. Very small embryonic-like stem cells (VSELs). Circ Res  2019; 124(2): 208-10.
 [http://dx.doi.org/10.1161/CIRCRESAHA.118.314287] [PMID:  30653438]

[127]
Bhartiya D, Unni S, Parte S, Anand S. Very small embryonic-like stem cells: implications in reproductive biology. BioMed Res Int  2013; 2013: 682326.
 [http://dx.doi.org/10.1155/2013/682326] [PMID:  23509758]

[128]
Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia  2006; 20(5): 857-69.
 [http://dx.doi.org/10.1038/sj.leu.2404171] [PMID:  16498386]

[129]
Ratajczak MZ, Ratajczak J, Suszynska M, Miller DM, Kucia M, Shin DM. A novel view of the adult stem cell compartment from the perspective of a quiescent population of very small embryonic-like stem cells. Circ Res  2017; 120(1): 166-78.
 [http://dx.doi.org/10.1161/CIRCRESAHA.116.309362] [PMID:  28057792]

[130]
Bhartiya D. Stem cells survive oncotherapy & can regenerate non-functional gonads: A paradigm shift for oncofertility. Indian J Med Res  2018; 148 (Suppl.): S38-49.
 [PMID:  30964080]

[131]
Virant-Klun I. Functional testing of primitive oocyte-like cells developed in ovarian surface epithelium cell culture from small vsel-like stem cells: Can they be fertilized one day? Stem Cell Rev Rep  2018; 14(5): 715-21.
 [http://dx.doi.org/10.1007/s12015-018-9832-y] [PMID:  29876729]

[132]
Sharara FI, Lelea LL, Rahman S, Klebanoff JS, Moawad GN. A narrative review of platelet-rich plasma (PRP) in reproductive medicine. J Assist Reprod Genet  2021; 38(5): 1003-12.
 [http://dx.doi.org/10.1007/s10815-021-02146-9] [PMID:  33723748]

[133]
Hajipour H, Farzadi L, Latifi Z, et al. An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects. Syst Biol Reprod Med  2021; 67(3): 177-88.
 [http://dx.doi.org/10.1080/19396368.2020.1862357] [PMID:  33632047]

[134]
Bos-Mikich A, de Oliveira R, Frantz N. Platelet-rich plasma therapy and reproductive medicine. J Assist Reprod Genet  2018; 35(5): 753-6.
 [http://dx.doi.org/10.1007/s10815-018-1159-8] [PMID:  29564738]

[135]
Sfakianoudis K, Rapani A, Grigoriadis S, et al. Novel approaches in addressing ovarian insufficiency in 2019: Are we there yet? Cell Transplant  2020; 29: 963689720926154.
 [http://dx.doi.org/10.1177/0963689720926154] [PMID:  32686983]

[136]
Everts PAM, Knape JTA, Weibrich G, et al. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol  2006; 38(2): 174-87.
 [PMID:  16921694]

[137]
Zhang S, Li P, Yuan Z, Tan J. Platelet-rich plasma improves therapeutic effects of menstrual blood-derived stromal cells in rat model of intrauterine adhesion. Stem Cell Res Ther  2019; 10(1): 61.
 [http://dx.doi.org/10.1186/s13287-019-1155-7] [PMID:  30770774]

[138]
Tomassetti C, D’Hooghe T. Endometriosis and infertility: Insights into the causal link and management strategies. Best Pract Res Clin Obstet Gynaecol  2018; 51: 25-33.
 [http://dx.doi.org/10.1016/j.bpobgyn.2018.06.002] [PMID:  30245115]

[139]
Olooto WE, Amballi AA, Banjo TA. A review of Female Infertility; important etiological factors and management. J Microbiol Biotechnol Res  2012; 2(3): 379-85.

[140]
Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open  2017; 2017(2): hox007.
 [http://dx.doi.org/10.1093/hropen/hox007] [PMID:  30895225]

[141]
Igboeli P, El Andaloussi A, Sheikh U, et al. Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: two case reports and a review of the literature. J Med Case Reports  2020; 14(1): 108.
 [http://dx.doi.org/10.1186/s13256-020-02426-5] [PMID:  32680541]

[142]
Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther  2017; 8(1): 11.
 [http://dx.doi.org/10.1186/s13287-016-0458-1] [PMID:  28114977]

[143]
Li J, Mao Q, He J, She H, Zhang Z, Yin C. Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism. Stem Cell Res Ther  2017; 8(1): 55.
 [http://dx.doi.org/10.1186/s13287-017-0514-5] [PMID:  28279229]

[144]
Hendriks S, Dancet EA, van Pelt AM, Hamer G, Repping S. Artificial gametes: a systematic review of biological progress towards clinical application. Hum Reprod Update  2015; 21(3): 285-96.
 [http://dx.doi.org/10.1093/humupd/dmv001] [PMID:  25609401]

[145]
Santamaria X, Cabanillas S, I Cervelló, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod  2016; 31(5): 1087-96.
 [http://dx.doi.org/10.1093/humrep/dew042] [PMID:  27005892]

[146]
Kokai LE, Marra K, Rubin JP. Adipose stem cells: biology and clinical applications for tissue repair and regeneration. Transl Res  2014; 163(4): 399-408.
 [http://dx.doi.org/10.1016/j.trsl.2013.11.009] [PMID:  24361334]

[147]
Ballios BG, Cooke MJ, van der Kooy D, Shoichet MS. A hydrogel-based stem cell delivery system to treat retinal degenerative diseases. Biomaterials  2010; 31(9): 2555-64.
 [http://dx.doi.org/10.1016/j.biomaterials.2009.12.004] [PMID:  20056272]
Rights & Permissions Print Cite
Article Metrics
60
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574888X17666220511142930	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946
Current Stem Cell Research & Therapy

Mesenchymal Stem Cell-based Therapy and Female Infertility: Limitations and Advances

Abstract

Graphical Abstract

Related Journals

Related Books
